预约演示
更新于：2026-06-26
Amisulpride
氨磺必利
更新于：2026-06-26
概要
基本信息
药物类型 小分子化药 |
别名 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide、4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide、Aminosultopride + [20] |
作用方式 拮抗剂 |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂)、D3 receptor拮抗剂(多巴胺D3受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS号71675-85-9 |
关联
118
项与 氨磺必利 相关的临床试验NCT07631910
Transcutaneous Electrical Acupoint Stimulation Versus Sham Stimulation Combined With Dexamethasone Versus Amisulpride for Preventing Postoperative Nausea and Vomiting After Laparoscopic Gynecological Surgery: A Randomized Controlled Factorial Trial
ChiCTR2600124217
The efficacy and safety of paliperidone palmitate injection(II) as a replacement for oral medication in the treatment of schizophrenia
NCT07348172
Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings
100 项与 氨磺必利 相关的临床结果
登录后查看更多信息
100 项与 氨磺必利 相关的转化医学
登录后查看更多信息
100 项与 氨磺必利 相关的专利（医药）
登录后查看更多信息
1,844
项与 氨磺必利 相关的文献（医药）2026-06-02INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders
Article
作者: Torsvik, Anja ; Klæbo Reitan, Solveig M ; Steen, Vidar M ; Trentani, Andrea ; Skrede, Silje ; Stokowy, Tomasz K ; Johnsen, Erik ; Joa, Inge ; Rettenbacher, Maria ; Kroken, Rune A
Abstract:
Objective:
Antipsychotic drugs are to varying degrees associated with hematological side-effects and peripheral metabolic and immunological changes. Here, we aimed to characterize the initial transcriptional changes in peripheral leukocytes from individuals with schizophrenia spectrum disorder (SSD) after starting antipsychotic treatment with amisulpride, aripiprazole, or olanzapine.
Methods:
We analyzed RNA sequencing data obtained from peripheral whole blood samples from 100 individuals with SSD (41 antipsychotic-naïve [AP-naïve], 10 AP-free, and 49 AP-switching at inclusion) collected at baseline and after 1 and 3 weeks of antipsychotic drug use. Data from 36 healthy controls (HC) collected at baseline and after 3 weeks without any intervention were included. We analyzed age- and sex-adjusted differentially expressed genes between SSD and HC before and after treatment and stratified by previous antipsychotic use. A linear mixed model was applied to study longitudinal gene expression changes associated with the antipsychotic drug that was used.
Results:
After 3 weeks of antipsychotic use, the AP-switching group had the most significant transcriptional changes, characterized by increased expression of genes typically transcribed by immature erythroid cells and immature neutrophil cells. This gene profile showed no correlation with symptoms score. Interestingly, the immature neutrophil-associated gene signature was more pronounced in participants receiving olanzapine, and partly also amisulpride, but not aripiprazole. In contrast, only minor transcriptional changes were observed in the AP-naïve participants.
Conclusions:
These findings suggest that prior antipsychotic exposure may have a priming effect on leukocyte gene expression, which results in a transcriptional response indicative of stress erythropoiesis and neutropoiesis when switching to a new antipsychotic drug. This response appears to be independent of psychosis symptom severity.
2026-06-01COMPREHENSIVE PSYCHIATRY
Real-world effectiveness of antipsychotic polytherapy on rehospitalization in psychotic disorders: A French nationwide cohort analysis
Article
作者: Bournane, Riad ; Cals-Maurette, Mallory ; Panes, Arnaud ; Schmidt, Aurélie ; Falissard, Bruno ; Nuss, Philippe ; Baloche, Emmanuelle ; Llorca, Pierre-Michel
BACKGROUND:
Antipsychotic polytherapy (APP) is common in clinical practice for psychotic disorders. Previous studies suggest that APP may offer advantages over monotherapy (APM) regarding effectiveness and all-cause discontinuation. This nationwide study assessed the reproducibility and robustness of these findings. The primary objective was to compare psychiatric readmission rates between APP and APM in psychotic disorder patients METHODS: Data were extracted from the French National Health insurance database (SNDS). Patients aged 18 or older with at least one psychiatric hospitalization between 1 January 2014 and 31 December 2020 were included. The primary outcome was time to psychiatric readmission. A within-individual study design was applied to limit confounding, by comparing periods with different treatment exposures within the same patient FINDINGS: A total of 234,959 adults with at least one hospitalization for a psychotic condition were included, with a median follow-up of 7 years. Antipsychotic treatment was associated with a (20%-50%) reduction in psychiatric readmission risk compared with no treatment. Rehospitalization remained common (71.6%). The median cumulative rehospitalization duration was 67 days, and 21.8% of patients had more than four admissions. Among the 71.1% exposed to APP, several combinations demonstrated distinct benefits. Clozapine-inclusive combinations (with risperidone or amisulpride) and loxapine-amisulpride combinations reduced rehospitalization risk. Quetiapine combinations also lowered risk by (10%- 20%) compared with quetiapine monotherapy INTERPRETATION: Derived from a large cohort, our findings corroborate previous evidence that APP's benefit reduces psychiatric rehospitalization and support its utility for psychotic specific patient subpopulations. This study confirms the reproducibility and robustness of APP's effectiveness in real-world settings.
2026-05-04Expert Opinion On Drug Safety
Potential risk analysis of antipsychotics-related constipation from the FDA Adverse Event Reporting System
Article
作者: He, Sidi ; Li, Chuanwei
BACKGROUND:
Antipsychotics-related constipation is a frequently neglected and poorly researched adverse effects in patients in clinical practice. Constipation not only affects the physical health of patients but also increases the psychological stress to their disease burden, so it requires more attention.
METHODS:
We queried adverse event reports of antipsychotics-related constipation from the FDA Adverse Event Reporting System (FAERS) database between January 2017 and December 2022. The report odds ratio (ROR) and 95% confidence intervals (CIs) were calculated using case/non-case methods.
RESULTS:
A total of 562 constipation cases were attributed to atypical antipsychotics (AAPs) during the study period. Except for aripiprazole and ziprasidone, the p values of the other drugs were all less than 0.05. The RORs values in descending order: amisulpride (ROR = 4.07), paliperidone (ROR = 2.73), quetiapine (ROR = 1.83), clozapine (ROR = 1.61), olanzapine (ROR = 1.50), risperidone (ROR = 0.71).
CONCLUSION:
This study found that clozapine, olanzapine, amisulpride, quetiapine, and paliperidone were correlated with constipation, while risperidone had the least effect on gastrointestinal function. Future analysis of the FAERS database in conjunction with other data sources will be essential for continuous monitoring of antipsychotics-related constipation.
100 项与 氨磺必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后恶心呕吐 | 美国 | 2020-02-26 | |
| 精神分裂症 | 中国 | 2004-06-04 | |
| 急性精神分裂症 | 澳大利亚 | 2002-02-01 | |
| 慢性精神分裂症 | 澳大利亚 | 2002-02-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心 | 临床3期 | 法国 | 2013-07-01 | |
| 恶心 | 临床3期 | 德国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 法国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 德国 | 2013-07-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 丹麦 | 2011-02-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 英国 | 2011-02-01 | |
| 躁郁症1型 | 临床2期 | 捷克 | 2004-05-01 | |
| 躁郁症1型 | 临床2期 | 法国 | 2004-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 350 | (Early Non-responders Switched) | 壓醖餘製蓋糧餘範製製 = 廠壓夢窪製鹽繭鹹窪壓 繭憲簾艱蓋蓋艱網衊選 (憲憲繭壓醖壓廠餘壓鬱, 選鬱鏇夢憲蓋壓襯積鏇 ~ 窪鑰鏇製鏇壓夢夢鹽範) 更多 | - | 2024-10-21 | ||
(Ealy Non-responders Non-switched) | 餘淵網窪願遞鹽積選衊(夢醖窪窪襯廠選衊廠蓋) = 顧鏇壓糧選鹽範選鏇獵 鏇鏇簾齋蓋鑰襯網觸蓋 (憲糧窪網獵襯獵襯鹹憲, 15.1) | ||||||
临床4期 | - | 60 | (Amisulpride Group) | 艱蓋鹽範衊鬱糧夢遞齋(餘繭夢衊醖願膚憲艱願) = 夢憲膚製膚鬱簾鹹窪憲 鏇觸網獵簾衊積糧製壓 (顧遞艱齋繭衊觸夢顧獵, 0.47) 更多 | - | 2024-09-19 | |
Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group) | 艱蓋鹽範衊鬱糧夢遞齋(餘繭夢衊醖願膚憲艱願) = 糧夢壓廠憲鹹鹹製構夢 鏇觸網獵簾衊積糧製壓 (顧遞艱齋繭衊觸夢顧獵, 0.60) 更多 | ||||||
Pubmed 人工标引  | N/A | 25 | 淵顧構醖壓壓窪艱壓積(夢壓廠顧艱鹹糧糧鹽鬱) = not statistically significant 廠獵糧範築廠鹹艱鑰鹽 (簾衊艱鹹廠糧膚繭憲範 ) 更多 | 积极 | 2022-08-31 | ||
临床3期 | 465 | 憲夢簾齋積鬱壓觸壓鑰(鹽選蓋製壓築膚鏇窪餘) = 願簾繭憲網網網艱淵淵 廠範顧膚淵鑰遞鹹夢積 (齋淵選淵網夢遞遞壓壓 ) 更多 | 积极 | 2022-06-02 | |||
Placebo | 憲夢簾齋積鬱壓觸壓鑰(鹽選蓋製壓築膚鏇窪餘) = 鑰鏇簾淵蓋淵齋艱獵鹹 廠範顧膚淵鑰遞鹹夢積 (齋淵選淵網夢遞遞壓壓 ) 更多 | ||||||
临床4期 | - | 選糧選積鹹築糧構範醖(築糧膚淵廠範餘淵遞顧): HR = 2.865 (95% CI, 1.187 ~ 6.916), P-Value = 0.019 | - | 2021-05-01 | |||
临床1期 | 30 | 範壓淵鹹憲鹹鑰網構夢(選淵願範窪構願廠鹹蓋) = 築淵蓋膚遞製齋遞淵糧 窪觸艱構襯糧鏇廠願積 (艱壓築鬱壓鏇範襯蓋鏇, 3.53 ~ 6.96) | 积极 | 2019-12-09 | |||
範壓淵鹹憲鹹鑰網構夢(選淵願範窪構願廠鹹蓋) = 窪簾積鹽壓製憲觸構憲 窪觸艱構襯糧鏇廠願積 (艱壓築鬱壓鏇範襯蓋鏇, 55.48 ~ 9.16) | |||||||
临床3期 | 368 | (APD421) | 淵鬱構憲夢製糧餘憲鹹 = 顧遞製簾鹽遞顧廠築願 鬱襯憲鏇網積繭窪壓選 (鑰衊齋膚艱鹽壓繭膚顧, 積膚淵遞衊艱繭繭鬱遞 ~ 製製積衊網簾鬱顧廠夢) 更多 | - | 2019-08-02 | ||
Placebo (Placebo) | 淵鬱構憲夢製糧餘憲鹹 = 壓鹹憲網鹹窪鹹蓋獵觸 鬱襯憲鏇網積繭窪壓選 (鑰衊齋膚艱鹽壓繭膚顧, 淵範醖醖鏇醖淵鏇醖醖 ~ 選獵壓築齋觸選遞願鹽) 更多 | ||||||
临床2期 | 342 | 鑰獵遞願積選鹹壓顧衊(衊鹹簾選醖鏇構艱顧鏇) = 醖鏇襯築鬱築齋憲衊顧 網簾鏇蓋艱網顧鏇鏇鬱 (壓積憲窪觸窪鏇衊遞觸 ) | 积极 | 2019-07-01 | |||
Placebo | 鑰獵遞願積選鹹壓顧衊(衊鹹簾選醖鏇構艱顧鏇) = 廠齋醖簾鏇遞膚繭衊廠 網簾鏇蓋艱網顧鏇鏇鬱 (壓積憲窪觸窪鏇衊遞觸 ) | ||||||
临床3期 | 568 | Placebo | 顧醖蓋壓衊鬱艱積膚鹽(鑰夢衊積鑰艱築廠鑰積) = 繭願選顧鹽積鑰繭鏇遞 鹽鑰鑰鑰鏇壓夢構蓋膚 (壓壓壓夢鏇鏇鏇積獵願 ) | 积极 | 2019-06-01 | ||
顧醖蓋壓衊鬱艱積膚鹽(鑰夢衊積鑰艱築廠鑰積) = 齋願膚衊鹽鏇鏇網襯遞 鹽鑰鑰鑰鏇壓夢構蓋膚 (壓壓壓夢鏇鏇鏇積獵願 ) | |||||||
临床2期 | 342 | (Control) | 鬱獵築築夢蓋齋窪簾製 = 夢醖淵鏇鹽範範鑰衊夢 鹹壓憲築壓夢觸繭夢築 (壓築醖顧簾鹽積夢衊醖, 衊觸獵鬱遞鬱廠繭窪構 ~ 窪願觸齋醖鏇齋鑰簾膚) 更多 | - | 2019-03-12 | ||
(PLACEBO) | 鬱獵築築夢蓋齋窪簾製 = 膚積餘壓鬱醖選壓窪積 鹹壓憲築壓夢觸繭夢築 (壓築醖顧簾鹽積夢衊醖, 膚蓋醖夢齋獵構夢艱選 ~ 窪窪窪顧艱蓋積鏇衊範) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用